We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Pancreatic Cancer
MedXY News
EnglishTag

Pancreatic Cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation
Gastroenterologyclinical trialimmunotherapy

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

By MedXY|Jan 8, 2026

A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo

Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity
GastroenterologyPancreatic Cancer

Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Jan 8, 2026

Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and syner

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer
Gastroenterologyimmunotherapyoncology

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

By MedXY|Jan 8, 2026

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of

Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer
GastroenterologymFOLFIRINOXneutropenia

Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer

By MedXY|Dec 29, 2025

A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported q

Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants
GastroenterologyIPMNMolecular Pathology

Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants

By MedXY|Dec 23, 2025

A large-scale cohort study demonstrates that mixed-type IPMNs have a three-fold higher prevalence of high-risk mutations compared to branch-duct variants, and that cyst fluid NGS provides superior diagnostic specificity over traditional cli

PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream
newsFOLFIRINOXPancreatic Cancer

PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream

By MedXY|Dec 8, 2025

In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety tre

Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial
newsAsparaginasePancreatic Cancer

Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial

By MedXY|Dec 8, 2025

In TRYBECA‑1, adding erythrocyte‑encapsulated L‑asparaginase (eryaspase) to second‑line chemotherapy did not improve overall survival, progression‑free survival, or response rates in advanced pancreatic ductal adenocarcinoma; adverse events

Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025
newsKRAS G12DPancreatic Cancer

Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025

By MedXY|Nov 24, 2025

A global phase I/II study of oral GFH375 in previously treated KRAS G12D mutant PDAC showed a 40.7% ORR, 96.7% DCR, median PFS 5.52 months, and manageable toxicity, supporting ongoing phase III evaluation.

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
newsmFOLFIRINOXneoadjuvant chemotherapy

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA

By MedXY|Nov 24, 2025

In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxici

Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial
General SurgerychemoradiotherapyFOLFIRINOX

Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial

By MedXY|Oct 15, 2025

The PREOPANC-2 trial compared neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer, finding no significant overall survival difference between the two regimens.

Minimally Invasive Surgery for Left-Sided Pancreatic Cancer: Long-Term Safety Confirmed by DIPLOMA Trial
General SurgeryPancreatic Cancer

Minimally Invasive Surgery for Left-Sided Pancreatic Cancer: Long-Term Safety Confirmed by DIPLOMA Trial

By MedXY|Oct 9, 2025

The DIPLOMA trial demonstrates that minimally invasive left pancreatectomy for resectable pancreatic cancer offers comparable long-term survival outcomes to open surgery, validating its oncologic safety and supporting its use in clinical pr

Do Oily Fish Intake Increase Pancreatic Cancer Risk?
Clinical UpdatesMendelian RandomizationPancreatic Cancer

Do Oily Fish Intake Increase Pancreatic Cancer Risk?

By MedXY|Oct 9, 2025

This Mendelian randomization study reveals a surprising association between higher oily fish consumption and increased pancreatic cancer risk, highlighting new directions for dietary guidance and pancreatic disease prevention.

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial
General Surgerychemoradiotherapyclinical trial

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial

By MedXY|Oct 7, 2025

The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model
Clinical Updatesearly detectionmachine learning

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

By MedXY|Oct 6, 2025

A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.

Statins: Beyond Heart Health—A New Weapon Against Cancer Prevention
Medical Newscancer preventionchronic inflammation

Statins: Beyond Heart Health—A New Weapon Against Cancer Prevention

By MedXY|Aug 30, 2025

Recent research uncovers that long-term statin use may prevent certain inflammation-driven cancers by blocking IL-33, heralding new possibilities in cancer prevention strategies.

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk
Medical NewsAlcoholepidemiology

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk

By MedXY|Oct 1, 2025

A large pooled analysis across continents confirms a linear, dose-dependent association between alcohol consumption and pancreatic cancer risk—independent of smoking status and with significant public health implications.

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial
Clinical UpdateschemotherapyFOLFIRINOX

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY|Sep 30, 2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.

Alcohol and Pancreatic Cancer: Emerging Evidence of Risk
newsAlcoholPancreatic Cancer

Alcohol and Pancreatic Cancer: Emerging Evidence of Risk

By MedXY|Sep 30, 2025

New research strengthens the link between alcohol consumption and pancreatic cancer, highlighting both dose-dependent and threshold risks.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities